Report on the analysis of tenders for INLYTA (axitinib, axitinib)

Category:

Description

The aim of the report is to present the dynamics of sales of Inlyta (international name: Axitinibum (aksytynib)) in the public procurement market.

Our study presents the sales of the medicine throughout 2021. The summary is a repository of both general and detailed knowledge. From the report, you will quickly find out in which Voivodships the medication was ordered and which locations posted tender procedures for its delivery.

The summary will help to prepare the offer estimates for those interested in entering the tender procedure. This is particularly important for companies that develop their offerings, by market knowledge, it is easier to scale up competitiveness.

This can also be a very helpful tool for the work of medical representatives.

The relevant information for potential bidders is the duration of the supply contract. This makes it much easier for those who are responsible for finding tenders and simply for preparing the offer, thanks to the increased time available.

Why should I take advantage of the offer?

The report contains specific data for one medication. In addition, we may add the value of the bundle and the winner to the summary.

What do you have to do to take advantage of this study?

Just contact us via the form, we will call you back to arrange the details.